| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BioAtla Inc. | Mecbotamab Vedotin (BA3011) | Solid Tumors | Phase 2 | Trial Completed | Intravenous | Oncology |
| BioCardia Inc. | CardiAMP (Heart Failure II) | Ischemic heart failure of reduced ejection fraction (HFrEF) | Phase 3 | Ongoing | Intracoronary | Cardiology |
| BioCardia Inc. | CardiAMP (BCDA-02) | Chronic Myocardial Ischemia | Phase 3 | Data Released | Intracoronary | Cardiology |
| BioCardia Inc. | CardiAMP (BCDA-01) | Ischemic Heart Failure | Phase 3 | Ongoing | Intracoronary | Cardiology |
| BioCryst Pharmaceuticals Inc. | BCX4161 - (OPuS-2) | Hereditary angioedema | Phase 2b | Trial Discontinued | Oral | Genetic Disorder |
| BioCryst Pharmaceuticals Inc. | BCX9930 - (RENEW) | Renal Complement-mediated Diseases | Phase 2 | Trial Discontinued | oral | Immunology |
| BioCryst Pharmaceuticals Inc. | BCX9930 - (REDEEM-2) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 2 | Trial Discontinued | Oral | Hematology |
| BioCryst Pharmaceuticals Inc. | BCX9930 - (REDEEM-1) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Trial Discontinued | Oral | Hematology |